Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22257195 | 0.88 | CYP1A2 (0.53) | RAB9APOLBNPC1MEN1KMT2A | |
| SCHEMBL22257196 | 0.86 | ALOX15 (0.52) | LMNA | |
| SCHEMBL25958471 | 0.86 | LMNA (0.43) | RAB9APOLBNPC1SMN1; SMN2LMNA | |
| SCHEMBL25958482 | 0.83 | POLB (0.47) | RAB9APOLBNPC1MEN1KMT2A | |
| SCHEMBL25958689 | 0.81 | RAB9A (0.50) | RAB9APOLBNPC1MEN1KMT2A | |
| SCHEMBL25958709 | 0.81 | RAB9A (0.50) | RAB9APOLBNPC1MEN1KMT2A | |
| SCHEMBL25958459 | 0.80 | POLB (0.49) | RAB9APOLBNPC1MEN1KMT2A | |
| SCHEMBL25958458 | 0.80 | RAB9A (0.51) | RAB9APOLBNPC1MEN1KMT2A | |
| SCHEMBL25958421 | 0.78 | RAB9A (0.47) | RAB9APOLBNPC1MEN1KMT2A | |
| SCHEMBL25958468 | 0.78 | POLB (0.49) | RAB9APOLBNPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248752-A1 | PRODRUGS OF ALOX-15 INHIBITORS AND METHODS OF USING THE SAME | EMPIRICO INC. | 2023-08-10 | — | — | US | disclosed |
| US-11666588-B2 | Prodrugs of ALOX-15 inhibitors and methods of using the same | EMPIRICO INC. (US) | 2023-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248752-A1 | PRODRUGS OF ALOX-15 INHIBITORS AND METHODS OF USING THE SAME | ALOX15, ALOX5, ALOX15B | RAB9A 4106/4885POLB 979/4885NPC1 2279/4885 |
| US-11666588-B2 | Prodrugs of ALOX-15 inhibitors and methods of using the same | ALOX15, ALOX5, ALOX15B | RAB9A 4106/4885POLB 979/4885NPC1 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.